Floatz logo

Anti-Cd19/Cd20/Cd22 Car T-Cells

Refractory Childhood Non-Hodgkin Lymphoma

Sumithira VasuCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Refractory Childhood Non-Hodgkin Lymphoma cohort.

Asset / SponsorPhaseRating
Fludarabine
Sumithira Vasu
Phase 1CC
Cyclophosphamide
Sumithira Vasu
Phase 1CC
cd22 car-transduced t cells
Sumithira Vasu
Phase 1CC

Same molecule, other indications

Anti-Cd19/Cd20/Cd22 Car T-Cells is also rated in:

Recurrent B Acute Lymphoblastic LeukemiaDormant
CC
Indicative ·
43 / 100
View asset →
Recurrent B-Cell Prolymphocytic LeukemiaDormant
CC
Indicative ·
43 / 100
View asset →
Recurrent Acute Lymphoblastic LeukemiaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →